Immuneering Corporation

IMRX · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$61,037-$53,472-$50,514-$33,536
Dep. & Amort.$385$352$797$159
Deferred Tax$0$0$0-$307
Stock-Based Comp.$6,501$5,727$0$1,803
Change in WC-$925-$975$1,717$900
Other Non-Cash$76-$602$3,898$130
Operating Cash Flow-$55,000-$48,969-$44,101-$30,851
Investing Activities
PP&E Inv.-$85-$343-$742-$61
Net Acquisitions$0$0$0$70
Inv. Purchases-$5,410-$44,661-$50,105-$75,626
Inv. Sales/Matur.$31,930$52,300$92,678$75,616
Other Inv. Act.$0$0$0-$75,616
Investing Cash Flow$26,435$7,296$41,831-$75,616
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$4,237$28,200$19$120,319
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$1,066$241$0$23,946
Financing Cash Flow$5,304$28,441$19$144,265
Forex Effect$0$0$0$0
Net Chg. in Cash-$23,261-$13,231-$2,251$37,798
Supplemental Information
Beg. Cash$59,406$72,637$74,888$37,090
End Cash$36,145$59,406$72,637$74,888
Free Cash Flow-$55,084-$49,311-$44,844-$30,912
Immuneering Corporation (IMRX) Financial Statements & Key Stats | AlphaPilot